Engineering SIM-1 and MZ-1 PROTACs for enhanced target degradation in KSHV-infected immortalized endothelial cells
- 1Department of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205 USA
- 2Department of Pharmacology, The Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 USA
Abstract
Kaposi’s Sarcoma-associated Herpesvirus (KSHV) is the etiologic agent of several human cancers, including Kaposi’s Sarcoma (KS), which are still lacking of treatment options. Members of the bromodomain and extra-terminal domain (BET) family, especially bromodomain-containing protein 4 (BRD4), play important roles in RNA polymerase II–mediated transcriptional regulation and are required for the expression of many tumor-driving oncogenes in various cancer cells. Therefore, BET proteins have become attractive targets for anticancer drug development. Our recent studies showed that KSHV-infected immortalized endothelial cells displayed strong resistance to BET inhibitors such as (+)-JQ1. In contrast, we found out MZ-1 and SIM-1, two of BRD4 PROTAC degraders, as effective inhibitors of cell growth in these cells. To develop PROTAC molecules with enhanced BRD4 degradation potency, we introduced an (S)-methyl group at the benzylic position of the VHL ligand in the VHL-based BRD4 PROTACs MZ-1 and SIM-1, thereby designing and generating MZ-1-ME and SIM-1-ME, respectively. In KS cellular model, MZ-1-ME and SIM-1-ME exhibited enhanced BRD4 degradation and anticancer activities compared with their parental compounds, which may represent promising PROTACs for development of BRD4-targeted therapies against KS.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12575-026-00360-2.
Related
- Ubiquitin ligase CHFR impairs Tie2 signaling via K48-linked ubiquitylation and degradation of Akt1 in endothelial cells
- Biofilm Engineering for Efficient Substrate‐Enzyme Interactions to Enhance Enzymatic PET Degradation
- ER Stress Induces Endothelial Dysfunction Linked to Mitochondrial Redox Imbalance and Enhanced Mitochondrial Bioenergetics in Penile Erectile Tissue
- Model-Guided Engineering of NS1-Truncated Influenza OP7 Particles with Enhanced Interferon-Mediated Antiviral Activity
- Discovery of Putative Phosphorylation Sites in Cre1 and Ace1 as Engineering Targets for Enhanced Cellulase Production in Trichoderma reesei
BibTeX
@article{chen2026engineering,
title = {{Engineering SIM-1 and MZ-1 PROTACs for enhanced target degradation in KSHV-infected immortalized endothelial cells}},
author = {Jungang Chen and Zhengyu Wang and Jarna Karmoker and Jiaojiao Fan and Hongfei Zhou and Lu Dai and Hong-Yu Li and Zhiqiang Qin},
journal = {Biological Procedures Online},
year = {2026},
month = aug,
doi = {10.1186/s12575-026-00360-2},
url = {https://doi.org/10.1186/s12575-026-00360-2},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Engineering SIM-1 and MZ-1 PROTACs for enhanced target degradation in KSHV-infected immortalized endothelial cells
AU - Jungang Chen
AU - Zhengyu Wang
AU - Jarna Karmoker
AU - Jiaojiao Fan
AU - Hongfei Zhou
AU - Lu Dai
AU - Hong-Yu Li
AU - Zhiqiang Qin
PY - 2026
DA - 2026/08/14
JO - Biological Procedures Online
DO - 10.1186/s12575-026-00360-2
UR - https://doi.org/10.1186/s12575-026-00360-2
AB - Kaposi’s Sarcoma-associated Herpesvirus (KSHV) is the etiologic agent of several human cancers, including Kaposi’s Sarcoma (KS), which are still lacking of treatment options. Members of the bromodomain and extra-terminal domain (BET) family, especially bromodomain-containing protein 4 (BRD4), play important roles in RNA polymerase II–mediated transcriptional regulation and are required for the expression of many tumor-driving oncogenes in various cancer cells. Therefore, BET proteins have become attractive targets for anticancer drug development. Our recent studies showed that KSHV-infected immortalized endothelial cells displayed strong resistance to BET inhibitors such as (+)-JQ1. In contrast, we found out MZ-1 and SIM-1, two of BRD4 PROTAC degraders, as effective inhibitors of cell growth in these cells. To develop PROTAC molecules with enhanced BRD4 degradation potency, we introduced an (S)-methyl group at the benzylic position of the VHL ligand in the VHL-based BRD4 PROTACs MZ-1 and SIM-1, thereby designing and generating MZ-1-ME and SIM-1-ME, respectively. In KS cellular model, MZ-1-ME and SIM-1-ME exhibited enhanced BRD4 degradation and anticancer activities compared with their parental compounds, which may represent promising PROTACs for development of BRD4-targeted therapies against KS. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12575-026-00360-2.
SN - 1480-9222
ER -